QNCX · Quince Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Lamond David Director | ▲ Buy | Open Market | 2,347,545 Shares held | 12/14/2023 | View profile |
| Dominy Stephen S. Chief Scientific Officer | ▲ Buy | Open Market | 1,217,086 Shares held | 11/12/2021 | View profile |
| Thye Dirk Chief Executive Officer | ▼ Sell | Gift | 739,885 Shares held | 12/10/2025 | View profile |
| Hannah Brendan Chief Business Officer | ▲ Buy | Option Exercise | 361,827 Shares held | 12/5/2025 | View profile |
| LOWE CHRISTOPHER P. COO & Chief Financial Officer | ▲ Buy | Grant | 265,000 Shares held | 3/3/2022 | View profile |
| Holsinger Leslie EVP, Preclinical Development | ▼ Sell | Tax Withholding | 148,080 Shares held | 6/6/2022 | View profile |
| Detke Michael J. Chief Medical Officer | ▲ Buy | Grant | 140,000 Shares held | 3/3/2022 | View profile |
| Ryan Charles S. PRESIDENT | ▲ Buy | Grant | 130,009 Shares held | 6/18/2025 | View profile |
| McDowell Caryn Gordon Chief Legal & Adm. Officer | ▼ Sell | Open Market | 122,500 Shares held | 6/6/2022 | View profile |
| Lynch Casey Chief Executive Officer | ▲ Buy | Option Exercise | 109,895 Shares held | 11/18/2021 | View profile |
| Low Philip S Director | ▲ Buy | Grant | 63,974 Shares held | 5/19/2022 | View profile |
| Benatti Luca | ▼ Sell | Open Market | 39,179 Shares held | 12/26/2025 | View profile |
| Monohon Ted Chief Accounting Officer & VP | ▼ Sell | Open Market | 27,440 Shares held | 3/6/2023 | View profile |
| Smith Karen L. Chief Medical Officer | ▲ Buy | Grant | 24,336 Shares held | 5/19/2022 | View profile |
| McLoughlin Margaret Director | ▲ Buy | Open Market | 8,000 Shares held | 8/8/2023 | View profile |
Transaction History
| Benatti Luca | ▼ Sell | Open Market | 50,000 | $174K | 12/26/2025 |
| Thye Dirk | ▼ Sell | Gift | 739,885 | $0 | 12/10/2025 |
| Thye Dirk | ▼ Sell | Gift | 739,885 | $0 | 12/10/2025 |
| Hannah Brendan | ▲ Buy | Option Exercise | 2,271 | $1K | 12/5/2025 |
| Hannah Brendan | ▲ Buy | Option Exercise | 25,280 | $24K | 12/5/2025 |
| Thye Dirk | ▲ Buy | Grant | 150,944 | $181K | 6/18/2025 |
| Ryan Charles S. | ▲ Buy | Grant | 7,548 | $9K | 6/18/2025 |
| Hannah Brendan | ▲ Buy | Grant | 37,736 | $45K | 6/18/2025 |
| Benatti Luca | ▼ Sell | Other | 8,918 | — | 10/23/2024 |
| Thye Dirk | ▲ Buy | Open Market | 77,000 | $54K | 8/30/2024 |
| Thye Dirk | ▲ Buy | Open Market | 77,500 | $53K | 8/29/2024 |
| Hannah Brendan | ▲ Buy | Open Market | 23,565 | $15K | 8/21/2024 |
| Hannah Brendan | ▲ Buy | Open Market | 2,280 | $1K | 8/21/2024 |
| Hannah Brendan | ▲ Buy | Open Market | 5,000 | $3K | 8/21/2024 |
| Ryan Charles S. | ▲ Buy | Open Market | 48,387 | $31K | 8/20/2024 |
| Hannah Brendan | ▲ Buy | Open Market | 2,500 | $2K | 8/20/2024 |
| Hannah Brendan | ▲ Buy | Open Market | 3,424 | $2K | 8/20/2024 |
| Hannah Brendan | ▲ Buy | Open Market | 2,155 | $1K | 8/19/2024 |
| Hannah Brendan | ▲ Buy | Option Exercise | 56,061 | $31K | 6/4/2024 |
| Thye Dirk | ▲ Buy | Option Exercise | 90,531 | $50K | 1/16/2024 |
| Thye Dirk | ▲ Buy | Option Exercise | 149,999 | $141K | 1/16/2024 |
| Lamond David | ▲ Buy | Open Market | 22,627 | $24K | 12/14/2023 |
| Lamond David | ▲ Buy | Open Market | 22,627 | $23K | 12/13/2023 |
| Lamond David | ▲ Buy | Open Market | 300 | $300 | 12/12/2023 |
| Lamond David | ▲ Buy | Open Market | 22,327 | $23K | 12/12/2023 |
| Lamond David | ▲ Buy | Open Market | 19,123 | $19K | 12/7/2023 |
| Lamond David | ▲ Buy | Open Market | 19,123 | $20K | 12/6/2023 |
| Lamond David | ▲ Buy | Open Market | 19,123 | $19K | 12/5/2023 |
| Lamond David | ▲ Buy | Open Market | 14,378 | $14K | 12/1/2023 |
| Lamond David | ▲ Buy | Open Market | 14,378 | $13K | 11/30/2023 |
| Lamond David | ▲ Buy | Open Market | 14,378 | $14K | 11/29/2023 |
| Lamond David | ▲ Buy | Open Market | 41,026 | $54K | 8/31/2023 |
| Lamond David | ▲ Buy | Open Market | 41,026 | $54K | 8/30/2023 |
| Lamond David | ▲ Buy | Open Market | 24,766 | $32K | 8/17/2023 |
| Lamond David | ▲ Buy | Open Market | 117,348 | $151K | 8/16/2023 |
| Lamond David | ▲ Buy | Open Market | 107,886 | $142K | 8/15/2023 |
| Thye Dirk | ▲ Buy | Open Market | 88,000 | $111K | 8/10/2023 |
| Thye Dirk | ▲ Buy | Open Market | 80,000 | $99K | 8/8/2023 |
| Hannah Brendan | ▲ Buy | Open Market | 71,762 | $88K | 8/8/2023 |
| McLoughlin Margaret | ▲ Buy | Open Market | 8,000 | $10K | 8/8/2023 |
| Monohon Ted | ▼ Sell | Open Market | 1,871 | $2K | 3/6/2023 |
| Monohon Ted | ▼ Sell | Tax Withholding | 1,640 | $1K | 12/5/2022 |
| Monohon Ted | ▼ Sell | Tax Withholding | 1,520 | $2K | 9/6/2022 |
| Monohon Ted | ▼ Sell | Tax Withholding | 1,529 | $5K | 6/6/2022 |
| Holsinger Leslie | ▼ Sell | Tax Withholding | 10,920 | $31K | 6/6/2022 |
| McDowell Caryn Gordon | ▼ Sell | Tax Withholding | 6,700 | $19K | 6/6/2022 |
| McDowell Caryn Gordon | ▼ Sell | Open Market | 10,800 | $31K | 6/6/2022 |
| Smith Karen L. | ▲ Buy | Grant | 24,336 | — | 5/19/2022 |
| Low Philip S | ▲ Buy | Grant | 455,309 | — | 5/19/2022 |
| Low Philip S | ▲ Buy | Grant | 63,974 | — | 5/19/2022 |
| Hannah Brendan | ▲ Buy | Grant | 16,224 | — | 5/19/2022 |
| Thye Dirk | ▲ Buy | Grant | 64,589 | — | 5/19/2022 |
| Lamond David | ▲ Buy | Grant | 200,002 | — | 5/19/2022 |
| Monohon Ted | ▲ Buy | Grant | 34,000 | $0 | 3/3/2022 |
| McDowell Caryn Gordon | ▲ Buy | Grant | 140,000 | $0 | 3/3/2022 |
| Holsinger Leslie | ▲ Buy | Grant | 155,500 | $0 | 3/3/2022 |
| Detke Michael J. | ▲ Buy | Grant | 140,000 | $0 | 3/3/2022 |
| LOWE CHRISTOPHER P. | ▲ Buy | Grant | 175,000 | $0 | 3/3/2022 |
| Lynch Casey | ▲ Buy | Option Exercise | 60,000 | $28K | 11/18/2021 |
| LOWE CHRISTOPHER P. | ▲ Buy | Option Exercise | 30,000 | $67K | 11/16/2021 |
| Dominy Stephen S. | ▲ Buy | Open Market | 763 | $11K | 11/12/2021 |
| McLoughlin Margaret | ▲ Buy | Option Exercise | 1,000 | $17K | 10/8/2021 |
| McLoughlin Margaret | ▼ Sell | Open Market | 1,000 | $89K | 10/8/2021 |
| LOWE CHRISTOPHER P. | ▲ Buy | Option Exercise | 4,963 | $272K | 10/5/2021 |
| LOWE CHRISTOPHER P. | ▼ Sell | Open Market | 4,963 | $489K | 10/5/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70
Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.